aTyr Pharma (LIFE) Tops Q4 EPS by 2c

Note: EPS may not be comparable

aTyr Pharma (NASDAQ: LIFE) reported Q4 EPS of ($0.39), $0.02 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc. (XP) Tops Q2 EPS by 8c
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown